Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
This clinical trial evaluated the efficacy and safety of vadadustat, an oral medication, compared to darbepoetin alfa, an established erythropoiesis-stimulating agent (ESA), for maintaining hemoglobin levels in hemodialysis patients transitioning from ESA therapy. The study involved 319 participants and was conducted by Akebia Therapeutics in collaboration with Otsuka Pharmaceutical Development & Commercialization.
Indication: Anemia
Modality: small molecule
Target: Anemia in Hemodialysis Patients
Sponsor: Akebia Therapeutics
Source URL: ClinicalTrials.gov
Source updated: May 22, 2025
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Anemia in Hemodialysis Patients
View original source fields
Condition raw: Anemia
Condition normalized: Anemia
Modality raw: Anemia
Modality normalized: small molecule
Target raw: Anemia in Hemodialysis Patients
Target normalized: Anemia in Hemodialysis Patients